Skip to main content

Amgen Q3 FY2026 results

  • AMGN · Nasdaq
  • Biotechnology
  • S&P 500
$465.67−0.30%Close 13 Nov 2026 · Market value $253.3B

Amgen reported revenue of $10.4 billion, up 8.5% from a year earlier, net income of $3.86 billion and diluted earnings per share of $7.08 against $5.93 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 3 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Amgen Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$10.37B$9.56B+8.5%
Gross profit$7.58B$6.47B+17.0%
Gross margin73.1%67.8%+5.4 pts
Operating income$3.71B$2.53B+46.9%
Operating margin35.8%26.4%+9.4 pts
Net income$3.86B$3.22B+20.1%
Diluted EPS$7.08$5.93+19.4%
Operating cash flow$4.24B$4.68B−9.5%
Capital expenditure$587.0M$436.0M+34.6%
Free cash flow$3.65B$4.25B−14.0%

Operating KPIs for the quarter

Amgen operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Product sales$9.9Bup 8.2%
Repatha revenue$1.1Bup 36.6%
EVENITY revenue$751.0Mup 38.8%
Prolia revenue$632.0Mdown 44.5%
ENBREL revenue$611.0Mup 5.3%
TEZSPIRE revenue$538.0Mup 42.7%
TEPEZZA revenue$526.0Mdown 6.1%
BLINCYTO revenue$496.0Mup 26.5%
Otezla revenue$481.0Mdown 17.8%
Nplate revenue$472.0Mup 3.3%
UPLIZNA revenue$451.0Mup 191.0%
KRYSTEXXA revenue$419.0Mup 30.9%
IMDELLTRA/IMDYLLTRA revenue$406.0Mup 128.1%
Vectibix revenue$335.0Mup 18.0%
KYPROLIS revenue$330.0Mdown 8.1%
Aranesp revenue$329.0Mdown 7.8%
XGEVA revenue$288.0Mdown 46.6%

Earlier quarters

Amgen results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$10.37B+8.5%$7.08
Q2 FY202630 Jun 2026$10.05B+9.5%$4.37
Q1 FY202631 Mar 2026$8.62B+5.8%$3.34
Q4 FY202531 Dec 2025$9.87B+8.6%$2.46
Q3 FY202530 Sep 2025$9.56B+12.4%$5.93
Q2 FY202530 Jun 2025$9.18B+9.4%$2.65
Q1 FY202531 Mar 2025$8.15B+9.4%$3.20
Q4 FY202431 Dec 2024$9.09B+10.9%$1.16

More on Amgen: financial statements · revenue · earnings per share

AMGN's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.